Drug Profile
Elasomeran/davesomeran - Moderna Therapeutics
Alternative Names: Adapted Spikevax COVID-2019 vaccine; Moderna bivalent COVID-19 vaccine; Spikevax bivalent original/omicron BA.4-5; SPIKEVAX-Bivalent-BA.1; SPIKEVAX-BIVALENT-BA.4/5Latest Information Update: 08 May 2023
Price :
$50
*
At a glance
- Originator Moderna Therapeutics
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered COVID 2019 infections
Most Recent Events
- 18 Apr 2023 Registered for COVID-2019 infections (In adolescents, In adults, In children, In infants, In the elderly, Prevention) in USA (IM)
- 17 Feb 2023 Registered for COVID-2019 infections (In adolescents, In adults, In children, Prevention) in Australia (IM)
- 17 Feb 2023 Therapeutic Goods Administration provisonally approves for elasomeran/davesomeran in COVID-2019 infections